Literature DB >> 11834666

The prognostic role of the ECG in primary pulmonary hypertension.

Eduardo Bossone1, Giuseppe Paciocco, Diana Iarussi, Angelo Agretto, Aldo Iacono, Brenda W Gillespie, Melvyn Rubenfire.   

Abstract

BACKGROUND/RATIONALE: Doppler echocardiography and invasive hemodynamic parameters reflective of right ventricular failure are associated with a poor prognosis in patients with primary pulmonary hypertension (PPH). The aims of the present study were to examine whether ECG features in patients with PPH are associated with a decrease in survival, and to determine the value of the ECG in risk stratification. METHODS/
RESULTS: We analyzed the ECG, New York Heart Association (NYHA) class, and hemodynamic parameters in 51 untreated patients with PPH (88% women; mean age, 41.7 years; 79% NYHA classes III and IV) evaluated between 1992 and 1998. Subsequent treatment included epoprostenol in 37 patients, calcium channel blockers in 10 patients, epoprostenol and atrial septostomy in 2 patients, and lung transplant in 3 patients. As of 1999, 16 patients had died. Based on Kaplan-Meier estimates, median survival was > 6.5 years and estimated survival at 1 year, 3 years, and 5 years was 86%, 71%, and 57%, respectively. Significant predictors of decreased survival by Cox regression analysis include pulmonary vascular resistance (PVR; hazard ratio [HR], 1.11 per Wood unit), cardiac index (HR, 0.22 per L/min/m(2)), p wave amplitude in lead II (HR, 3.06 per mm), p > or = 0.25 mV in lead II (HR, 2.77), qR in V(1) (HR, 3.55), and World Health Organization criteria for right ventricular hypertrophy (HR, 4.26). After controlling for PVR, the HRs attributable to the ECG criteria were only slightly diminished. NYHA class and pulmonary artery pressures did not correlate with a decrease in survival.
CONCLUSIONS: ECG parameters reflective of physiologic and anatomic abnormalities in the right ventricle are associated with decreased survival in patients with PPH, and may be useful for deciding therapeutic choices including the timing for lung transplantation listing.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11834666     DOI: 10.1378/chest.121.2.513

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  26 in total

Review 1.  Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy.

Authors:  Jennifer L Snow; Steven M Kawut
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

2.  Giant P waves after pharmacological cardioversion of atrial fibrillation.

Authors:  Girolamo Catapano-Minotti; Andrea Corsonello; Raffaele Antonelli Incalzi
Journal:  Intern Emerg Med       Date:  2008-12-03       Impact factor: 3.397

Review 3.  Pulmonary hypertension in patients with heart failure and preserved ejection fraction: differential diagnosis and management.

Authors:  Nehal Hussain; Athanasios Charalampopoulos; Sheila Ramjug; Robin Condliffe; Charlie A Elliot; Laurence O'Toole; Andrew Swift; David G Kiely
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

4.  The Value of the Electrocardiogram for Evaluating Prognosis in Patients with Idiopathic Pulmonary Arterial Hypertension.

Authors:  Xiao-Ling Cheng; Jian-Guo He; Zhi-Hong Liu; Qing Gu; Xin-Hai Ni; Zhi-Hui Zhao; Qin Luo; Chang-Ming Xiong
Journal:  Lung       Date:  2016-11-25       Impact factor: 2.584

Review 5.  Evaluation and classification of pulmonary arterial hypertension.

Authors:  Sandeep Sahay
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

6.  Impact of the Right Ventricular Sokolow-Lyon Index in Children with Idiopathic Pulmonary Arterial Hypertension.

Authors:  Johannes Krämer; Felix Kreuzer; Michael Kaestner; Peter Bride; Fabian von Scheidt; Jannos Siaplaouras; Heiner Latus; Dietmar Schranz; Christian Apitz
Journal:  Pediatr Cardiol       Date:  2018-03-14       Impact factor: 1.655

7.  Non-invasive screening for pulmonary hypertension in idiopathic pulmonary fibrosis.

Authors:  Laith Alkukhun; Xiao-Feng Wang; Mostafa K Ahmed; Manfred Baumgartner; Marie M Budev; Raed A Dweik; Adriano R Tonelli
Journal:  Respir Med       Date:  2016-06-02       Impact factor: 3.415

Review 8.  WHO's in second?: A practical review of World Health Organization group 2 pulmonary hypertension.

Authors:  Sif Hansdottir; Dayna J Groskreutz; Brian K Gehlbach
Journal:  Chest       Date:  2013-08       Impact factor: 9.410

9.  Pulmonary hypertension: the role of the electrocardiogram.

Authors:  I R Henkens; R W C Scherptong; K W van Kralingen; S A M Said; H W Vliegen
Journal:  Neth Heart J       Date:  2008-08       Impact factor: 2.380

10.  Electrocardiography at diagnosis and close to the time of death in pulmonary arterial hypertension.

Authors:  Adriano R Tonelli; Manfred Baumgartner; Laith Alkukhun; Omar A Minai; Raed A Dweik
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-12-30       Impact factor: 1.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.